Send to

Choose Destination
J Clin Aesthet Dermatol. 2018 May;11(5):15-20. Epub 2018 May 1.

Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial.

Author information

Drs. Awal and Kaur are with the Department of Dermatology, Venereology, and Leprosy and Sri Guru Ram Das Institute of Medical Sciences and Research in Amritsar, India.


Background: Various treatment modalities have been described in the literature for treating warts, but none thus far have demonstrated optimal results. Recently, the mumps, measles, and rubella (MMR) antigen has gained popularity because of its proven efficacy in the treatment of warts. Aim: The goal was to evaluate the efficacy and safety of intralesional MMR antigen in the treatment of cutaneous warts. Methods: Patients were divided into an MMR (study) group and a normal saline (control) group. Injections were administered into the single largest wart on each patient every two weeks. Follow-up was done at six weeks and 16 weeks after the last injection for any side effects and/or recurrence. Results: Out of 150 patients, 72 received the MMR injection and 50 received normal saline injections. Twenty-eight patients did not complete the study. A statistically significant (p<0.00001) difference in results was found between the two groups: 68 percent of patients in the MMR group showed complete response compared to 10 percent in the control group. Pain during injection was the most common side effect and was seen in both groups. Conclusion: MMR injection has shown significant results with almost negligible adverse effects. The MMR antigen vaccine has therapeutic potential as a treatment for warts with its demonstrated efficacy, safety profile, and cost-effectiveness.


Immunotherapy; MMR vaccine; cutaneous warts


Conflict of interest statement

FUNDING:No funding was provided for this article. DISCLOSURES:The authors have no conflicts of interest relevant to the content of this article.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center